Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Bullboard Posts
Post by tuesdaynightridon Jan 11, 2015 8:55am
284 Views
Post# 23306796

Warning Signs

Warning SignsAs mentioned, after today I will be leaving for an extended period of time as I see TLT going thru a major valley over the next 9 months before it potentially climbs the mountain. I categorize my reasons as Warning Signs: (1) TLC-2000 HC approval: Management has never indicated a submittal date. I suspect that since this is a more advanced unit, that HC may have wanted more proof of concept rather than theory... so why not just say that or other. Obviously, this has major implications for funding. (2) Funding: Some of you are capable of going onto Sedar to pull up the 3rd q financials ($2 million in cash remaining at end Sept). Unfortunately, based on last years 4th q financials, you won't see 4th q financials until April 30th (4th q for all companies is always slowest). Some of you should pull up the salaries and the new staffing levels from the website... there are now 20+ individuals on payroll. This does not include all of the external activity costs... these easily exceed $1 million per quarter which is why something has to happen with funding shortly. I place a massive share issuance at 75% and a bad pharma deal at 25% (Roger has actually previously alluded to prior offers but was not specific... imagine that). (3) Preclinical trials: The mice trials were subcutaneous with tumor growth to 5mm. The rat trials were inside the bladder and allowed to grow to 1mm before treatment. Tumor was eradicated but validation similar to mice?? Why not allow these to grow to 5mm? Bencro says that Dr. Lilge answered this? In Bencro's of Lilge interpretation, the tumor size/challenge doesn't matter? Is this what Lilge meant? W/o any data? I think not. More on this later today when I discuss my findings on human bladder cancer. I was expecting further data from preclinical. Some on this board asked, "are there more trial results expected"? No response but maybe I will be surprised tomorrow when additional preclinical data is released! (4) Catalysts: I held out selling my 100k shares on Friday to get to 101k remaining because I kept expecting TLC-2000 announcement or add'l preclinical data. I would have rather sold this 100k at $0.50 rather than $0.39 avg but funding is red flag. a.) TLC-2000 approval- Short term effect as shareholders will realize very little TLC revenue for 1st q... maybe even less than 4th q. b.) Preclinical data: Is there more data to follow from U of T or PM? Question was asked but no response! Maybe a positive surprise or not! c.) Funding: This is what is keeping Roger up at night! He is asking himself, "what do I do? Take the bad deal or come with massive share issuance"? We will all know soon enough! d.) Pharma purchase out of the blue: Possible which is one reason I keep the 101k shares. The "used car" salesman could surprise me! e.) Most like catalyst scenario= none: What I mean to say here is you're looking at dead time for the next 6 to 9 months. (5) Independent analysis: The only recent analysis done was by Zack's issued 12/3/2014... PLEASE READ IT! This is one of the most inaccurate analysis's I've ever read. Either Anita at Zach's is completely incompetent or she contacted TLT for this report and was given completely false information. Relative to Korelin, since they are all now investors in Theralase and Tharalase is an advertiser on their website (conflict of interest?), you do not hear them ask Roger any questions of substance unlike their summer interviews. g.) TLT Communication: Unquestionably the thing that has made me the most bitter. It is the thing that has transformed me from a "goo goo" eyed investor in the science of TLT to a trader (yeah call me a traitor if it makes you feel good). The bottom line is that I've seen Roger evolve from the most gregarious forthcoming individual in early 2014 (he couldn't keep his mouth shut... 2 weeks couldn't pass w/o his being interviewed or issuing a PR) to an evasive non- communicative CEO. (How about his use of the word, "ABSOLUTELY" when starting the answer to a question). Anyway, good luck... I'll have some final thoughts this afternoon as this is time I do not have this morning.
Bullboard Posts